Fox Chase Cancer Center News

PHILADELPHIA (October 12, 2021)—When people think of global warming and climate change, they tend to think of melting glaciers, rising sea levels, and drought. They do not, however, generally think of obesity and other potential health effects.

PHILADELPHIA (October 6, 2021)—Fox Chase Cancer Center recently welcomed a new class of 21 Biomedical Sciences graduate students from the Lewis Katz School of Medicine at Temple University to introduce them to research faculty with whom they can do scientific rotations and ultimately their thesis research.

PHILADELPHIA (October 6, 2021)—Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center, has been named one of three winners of the second annual Lung Cancer Heroes awards program.

PHILADELPHIA (October 5, 2021)—In a recently published study, a researcher at Fox Chase Cancer Center outlined new methods for handling heterogeneous data types from large-scale studies. These studies generate genomic profiles with the goal of identifying subgroups of patients who may have a better prognosis or benefit from a particular treatment.

PHILADELPHIA (October 1, 2021)—The Bucks County Chapter of the Board of Associates of Fox Chase Cancer Center will host its 24th annual art show and sale in memory of George Bramhall.  Proceeds will benefit small cell lung cancer (SCLC) research at Fox Chase. This virtual art show and sale will take place from October 1 through November 30, 2021. Due to COVID-19 risks, this virtual event will temporarily replace the popular two-day in-person art show that has taken place annually. 

PHILADELPHIA (September 27, 2021)—In a recent study, a researcher at Fox Chase Cancer Center outlined new methods for predicting cancer survival and outcomes from studies that utilize large-scale genomic profiling of tumor samples from different cancers.

PHILADELPHIA (September 22, 2021)—In a recent study, researchers at Fox Chase Cancer Center examined over 200 patients with gastrostomy tubes and highlighted the need for a multidisciplinary approach to palliative care decision making for cancer patients.

PHILADELPHIA (September 22, 2021)—Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, today announced a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center. The research, to be carried out by the laboratory of Johnathan Whetstine, PhD, the institute’s director, will help identify new indications and potential biomarkers for Salarius’ lead drug candidate, seclidemstat.